Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis

BACKGROUND: The added value of radiotherapy following neoadjuvant FOLFIRINOX chemotherapy in patients with resectable or borderline resectable pancreatic cancer ((B)RPC) is unclear. The objective of this meta-analysis was to compare outcomes of patients who received neoadjuvant FOLFIRINOX alone or c...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, Quisette P., van Dam, Jacob L., Kivits, Isabelle G., Besselink, Marc G., van Eijck, Casper H. J., Homs, Marjolein Y. V., Nuyttens, Joost J. M. E., Qi, Hongchao, van Santvoort, Hjalmar J., Wei, Alice C., de Wilde, Roeland F., Wilmink, Johanna W., van Tienhoven, Geertjan, Groot Koerkamp, Bas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Pancreatic Tumors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591030/
https://www.ncbi.nlm.nih.gov/pubmed/34142290
http://dx.doi.org/10.1245/s10434-021-10276-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591030/
https://www.ncbi.nlm.nih.gov/pubmed/34142290
http://dx.doi.org/10.1245/s10434-021-10276-8

Ejemplares similares